MO-BENSON-HILL
18.1.2023 13:01:35 CET | Business Wire | Press release
Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), a food tech company unlocking the natural genetic diversity of plants, announced today that it became one of the first U.S.-based ingredient providers to achieve the international ProTerra Certification, a rigorous global standard that sets the bar for sustainable agricultural practices and labor practices as well as segregated non-GMO programs and more. Benson Hill also joins the respected ProTerra Network, a group of companies dedicated to sustainable practices and continuous improvement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005254/en/
Benson Hill Achieves ProTerra Sustainability Certification for its Proprietary Non-GMO Soy Portfolio. The company is one of the first U.S.-based ingredient providers to verify its sustainable practices under rigorous global standard. (Photo: Business Wire)
The ProTerra Certification program promotes social and environmental sustainability through food and feed supply chains, to support efforts to continuously improve day-to-day business operations and to help organizations to engage and implement the concept of sustainable development.
Throughout an extensive certification process, Benson Hill completed audits of its Creston, Iowa, and Seymour, Ind., plants as well as two shipping ports that store and transport its non-GMO soymeal. Benson Hill also partnered with its growers to conduct several on-farm visits. These in-depth audits examined data related to identity preservation along with deforestation practices, biodiversity efforts, and other Environmental, Social and Governance (ESG) metrics such as fair labor practices.
“I am delighted to welcome Benson Hill as a ProTerra Network Member. This certification demonstrates their engagement to continuously improve agricultural practices and achieve full transparency in the food supply chain,” said Emese van Maanen, Managing Director for the ProTerra Foundation. “Collaboration with farmers is essential to developing long-term relationships that create benefits from plant to plate.”
“Through our journey with ProTerra we gained important insights to solidify our position as a global ingredients company focused on responsible growth,” said Andres Martin, Executive Vice President and General Manager, International for Benson Hill. “Achieving the ProTerra certification standard is a testament to the ESG principles guiding our work to sustainably deliver our non-GMO soybean portfolio to markets within and outside the United States.”
The ProTerra standard, against which organizations are certified, is based on the Basel Criteria for Responsible Soy (created by Coop Switzerland and World Wildlife Fund). Today the standard is applicable to all sectors of the food and agricultural system worldwide and at all stages of the food chain. In addition, ProTerra certification ensures that high quality supplies of crops, food, and feed, that are independently certified as non-GMO and produced with improved sustainability, are available on the global market. Benson Hill’s proprietary soy ingredient portfolio, designed to meet specific end uses with less processing and increased traceability, is currently available in North America and in Europe.
Benson Hill built its closed-loop business model on sustainable design and systems thinking, which means its products deliver benefits across the entire value chain, from seed to plate. For example, CleanCRUSH™ ingredients derived from the company’s proprietary soybean genetics are designed as a less-processed alternative to commodity soy protein concentrate (SPC). CleanCRUSH ingredients can also reduce the need for costly energy- and water-intensive protein concentrating steps traditionally required for plant-based protein and aquaculture feed applications. In SPC comparisons, this can result in up to a 50 to 90 percent reduction in CO2e, depending on the ingredient source, and up to a 70 percent reduction in water usage.
For more information about Benson Hill’s progress in assessing impact and setting the pace of innovation in food, download its inaugural Environmental, Social and Governance (ESG) Report released in July 2022.
About Benson Hill
Benson Hill moves food forward with the CropOS® platform, a cutting-edge food innovation engine that combines data science and machine learning with biology and genetics. Benson Hill empowers innovators to unlock nature’s genetic diversity from plant to plate, with the purpose of creating nutritious, great-tasting food and ingredient options that are both widely accessible and sustainable. More information can be found at bensonhill.com or on Twitter at @bensonhillinc.
About ProTerra Foundation
The ProTerra Foundation is a not-for-profit organization located in the Netherlands that advances and promotes sustainability at all levels of the feed and food production system. Its mission is to be a global network of businesses supporting more sustainable agricultural practices in the agribusiness supply chains. The ProTerra Standard has been developed to promote social and environmental sustainability through the food and feed supply chains, to support stakeholders in their efforts to continuously improve their day-to-day business and to help organizations in engaging and implementing the concept of sustainable development. For details, please visit www.proterrafoundation.org.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, among other things, statements regarding: the anticipated benefits of the Company’s ProTerra certification, ongoing sustainability and ESG initiatives, and farmer collaborations; the Company’s plans to promote sustainable agricultural practices and enhanced food supply chain transparency; anticipated advantages of the Company’s CleanCRUSH ingredients, including expectations regarding reduced carbon emissions and water usage; industry conditions and trends; the Company’s strategy and plans for growth; the expected future performance of and demand for the Company’s products; the Company’s ability to manage, develop and sustainably deliver its products to domestic and international markets; expectations about the markets in which the Company participates; and statements regarding the Company’s competitive positioning, resources, capabilities, and expectations for future performance. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, risks associated with: the Company’s ability to realize the expected benefits of its ProTerra certification and to maintain its ProTerra certification; the Company’s ability to realize benefits associated with its ongoing sustainability and ESG initiatives and farmer collaborations; the success of the Company’s products and their ability to achieve expected results, including results related to sustainability benefits; the Company’s ability to grow and achieve growth profitably; the Company’s ability to maintain relationships with its customers, suppliers and strategic partners; changing industry conditions and consumer preferences; the Company’s ability to retain key personnel and generally execute on its business strategy; global and regional economic, agricultural, financial and commodities markets; political, social and health conditions, both domestically and internationally; the Company’s transition to becoming a public company; the effectiveness of the Company’s risk management strategies; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in our filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. We expressly disclaim any duty to update these forward-looking statements, except as otherwise required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005254/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
